Ancestim biosimilar - Profarma

Drug Profile

Ancestim biosimilar - Profarma

Alternative Names: PF-09; Recombinant human stem cell factor - Profarma; Recombinant SCF - Profarma

Latest Information Update: 26 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Profarma
  • Class Antianaemics; Antineoplastics; Stem cell factors
  • Mechanism of Action Colony stimulating factor stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 17 Jun 2015 Early research in Cancer in Lithuania (Parenteral) (Profarma pipeline, June 2015)
  • 02 Apr 2015 Profarma has patent protection for ancestim biosimilar (Profarma website, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top